TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35075679

Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (esomeprazole 20 mg 4 times daily and amoxicillin 1000 mg 3 times daily for 14 days)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, all twice daily for 14 days)
Number of subjects: 700
Study: 34032663

Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg/kg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Neostigmine (0.07 mg/kg to a maximum of 5 mg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sugammadex and Neostigmine
Number of subjects: 68
Study: 33405300

Group type: EXPERIMENTAL
Intervention: Multidisciplinary education intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fitbit smartwatch for measuring activity
Number of subjects: 12
Study: 33724204

Group type: EXPERIMENTAL
Intervention: Smartphone app intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 200
Study: 32144438

Group type: EXPERIMENTAL
Intervention: Placebo resembling psilocybin
Number of subjects: 33
Study: 35442179

Group type: EXPERIMENTAL
Intervention: HCP Plus Peer
Number of subjects: 292

Group type: COMPARATOR
Intervention: HCP support
Number of subjects: 292
Study: 33296786

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block with 30 ml of 0.2% ropivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (30 ml of 0.9% saline)
Number of subjects: 64
Study: 35991210

Group type: EXPERIMENTAL
Intervention: LY3127804 (20 mg/kg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 34463432

Group type: COMPARATOR
Intervention: Islatravir (MK-8591) single doses (5 mg to 400 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Islatravir (MK-8591) multiple doses (10 mg, 30 mg, 100 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Islatravir (MK-8591)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Islatravir (MK-8591) single doses (greater than or equal to 5 mg)
Number of subjects: 32
Study: 33226482

Group type: EXPERIMENTAL
Intervention: Complete Span‐Epiphyseal Ring (CSER)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Half Span‐Epiphyseal Ring (HSER)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Higher cage-height (HH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal cage-height (NH)
Number of subjects: 24
Study: 32379638

Group type: EXPERIMENTAL
Intervention: Qigong exercise (12-week intervention)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham Qigong (12-week intervention)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham Qigong
Number of subjects: 17
Study: 36063194

Group type: EXPERIMENTAL
Intervention: Cystocele repair with mesh (vaginal or laparoscopic approach)
Number of subjects: 205
Study: 33309977

Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 0

Group type: COMPARATOR
Intervention: SoC
Number of subjects: 0
Study: 32312713

Group type: EXPERIMENTAL
Intervention: 50 mg SDG/day (Brevail)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 180
Study: 35461260

Group type: EXPERIMENTAL
Intervention: On-site integrated care model with adherence counseling
Number of subjects: 500

Group type: COMPARATOR
Intervention: Referral to off-site clinics assisted by a patient navigator
Number of subjects: 500
Study: 33371741

Group type: EXPERIMENTAL
Intervention: Custom resting hand splint
Number of subjects: 19

Group type: COMPARATOR
Intervention: Prefabricated resting hand splint
Number of subjects: 19
Study: 34693932

Group type: EXPERIMENTAL
Intervention: De Simone Formulation Probiotic (DSFP; 'Visbiome') for 48 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 29
Study: 32448770

Group type: EXPERIMENTAL
Intervention: Tocilizumab intravenously
Number of subjects: 51
Study: 35829773

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite gel (NaOCl)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel (CHX)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 62
Study: 34934026

Group type: EXPERIMENTAL
Intervention: Digital Cognitive Aid (CA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No Digital Cognitive Aid
Number of subjects: 72
Study: 33983371

Group type: EXPERIMENTAL
Intervention: 3-day regimen of Pyronaridine-artesunate (180:60 mg)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 2-day regimen of Pyronaridine-artesunate (180:60 mg)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 1-day regimen of Pyronaridine-artesunate (180:60 mg)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 303
Study: 34229742

Group type: EXPERIMENTAL
Intervention: Curcumin-piperine capsules (3 capsules/day; 1500 mg curcumin and 15 mg piperine daily) for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules (3 capsules/day; 1515 mg maltodextrin daily) for 7 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Curcumin-piperine capsules
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study: 36332652

Group type: EXPERIMENTAL
Intervention: Combination HIV prevention package including immediate ART initiation
Number of subjects: 3570

Group type: EXPERIMENTAL
Intervention: Combination HIV prevention package excluding immediate ART initiation
Number of subjects: 3570

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 3570
Study: 32343994

Group type: EXPERIMENTAL
Intervention: Electronic cigarette (nicotine concentration of 12 mg/ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional cigarettes
Number of subjects: 40
Study: 35710251

Group type: EXPERIMENTAL
Intervention: adaptive, digital game‐based attention training programme
Number of subjects: 104

Group type: COMPARATOR
Intervention: numeracy programme
Number of subjects: 104
Study: 33076964

Group type: EXPERIMENTAL
Intervention: Intramuscular 120 mg methylprednisolone followed by methotrexate (increasing dose to 25 mg/week orally)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (injection and tablets)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Intramuscular 120 mg methylprednisolone followed by methotrexate
Number of subjects: 230
Study: 36205701

Group type: EXPERIMENTAL
Intervention: Single-point injection of 2 U of botulinum toxin type A per side (simplified method)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Individualized method with 2 to 5 U of botulinum toxin type A (total, 4 to 10 U) injected at one or two sites
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both methods (simplified and individualized)
Number of subjects: 55
Study: 34481432

Group type: EXPERIMENTAL
Intervention: Intravenous administration of cytoflavin daily for 10 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard post-COVID rehabilitation protocol (pulse magnetic therapy, inhalation therapy, aeroion therapy, infrared laser therapy, course aerobic training, psychotherapy, and standard drug therapy)
Number of subjects: 45
Study: 35382763

Group type: EXPERIMENTAL
Intervention: SLIPA-3G
Number of subjects: 220

Group type: COMPARATOR
Intervention: LMAS
Number of subjects: 220
Study: 34133366

Group type: EXPERIMENTAL
Intervention: 3D printing and virtual planning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional free fibula flap
Number of subjects: 40
Study: 32726268

Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 2883

Group type: EXPERIMENTAL
Intervention: Lactate ≥4 mmol/L
Number of subjects: 2883

Group type: EXPERIMENTAL
Intervention: Lactate ≥7 mmol/L
Number of subjects: 2883

Group type: EXPERIMENTAL
Intervention: Lactate <4 mmol/L
Number of subjects: 2883
Study: 35511718

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg 3 times/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (3 times/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 13
Study: 32895056

Group type: EXPERIMENTAL
Intervention: Anticoagulation with bivalirudin intravenously with a target aPTT of 45-70 sec for three days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment with low-molecular-weight heparins/unfractionated heparin subcutaneously
Number of subjects: 100
Study: 35815855

Group type: EXPERIMENTAL
Intervention: Active cTBS (n = 11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham cTBS (n = 9)
Number of subjects: 19
Study: 33421265

Group type: EXPERIMENTAL
Intervention: ET-GP ablation
Number of subjects: 67

Group type: COMPARATOR
Intervention: PVI
Number of subjects: 67
Study: 32457078

Group type: EXPERIMENTAL
Intervention: 250 mcg methylcobalamin
Number of subjects: 720

Group type: COMPARATOR
Intervention: 50 mcg (quasi control)
Number of subjects: 720
Study: 35986460

Group type: EXPERIMENTAL
Intervention: Remin Pro Forte (3-month program of hydroxyapatite, fluoride, xylitol, ginger, curcuma-containing cream)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Remin Pro (3-month cream regimen including hydroxyapatite and fluoride, xylitol)
Number of subjects: 20
Study: 33608405

Group type: EXPERIMENTAL
Intervention: Early closure strategy (between 30 and 40 days from rectal surgery)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Late closure strategy (after the end of adjuvant therapy)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Early closure strategy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Late closure strategy
Number of subjects: 28
Study: 33725262

Group type: EXPERIMENTAL
Intervention: Children born to mothers with connective tissue diseases (CTD)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Children born to mothers with chronic arthritis
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Children with neurodevelopmental disorders (ND)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Prenatal exposure to maternal autoantibodies or anti-rheumatic drugs
Number of subjects: 299
Study: 34188630

Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope
Number of subjects: 30

Group type: COMPARATOR
Intervention: C-MAC video laryngoscope
Number of subjects: 30
Study: 32281113

Group type: EXPERIMENTAL
Intervention: Proximal corticosteroid injection (40 mg of methylprednisolone injected 2 cm proximal to the wrist crease)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Distal corticosteroid injection (40 mg of methylprednisolone injected 2 to 3 cm distal to the wrist crease)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Proximal corticosteroid injection
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Distal corticosteroid injection
Number of subjects: 131
Study: 36305278

Group type: COMPARATOR
Intervention: Zumba (ZG)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Football (FG)
Number of subjects: 107
Study: 33565243

Group type: EXPERIMENTAL
Intervention: Low-power fractional CO2 laser combined with topical tranexamic acid (TXA) applied twice a day for 3 weeks, four times in total.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what treatment was used).
Number of subjects: 0
Study: 32379976

Group type: EXPERIMENTAL
Intervention: T'ai chi intervention (36-week program with varying class frequency)
Number of subjects: 18
Study: 32073793

Group type: EXPERIMENTAL
Intervention: Basophil activation test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double-blind, placebo-controlled food challenge test
Number of subjects: 0
Study: 35064189

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet plus fecal microbiota transplantation (FMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32424691

Group type: EXPERIMENTAL
Intervention: Dentifrice B (1.100 ppmF-NaF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dentifrice A (containing no fluoride)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 30
Study: 35259259

Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32135451

Group type: EXPERIMENTAL
Intervention: NMT plus VCIs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NMT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 60
Study: 34273556

Group type: EXPERIMENTAL
Intervention: verum IAF-tACS
Number of subjects: 84

Group type: COMPARATOR
Intervention: sham IAF-tACS (placebo)
Number of subjects: 84
Study: 32677452

Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin
Number of subjects: 0
Study: 33370551

Group type: EXPERIMENTAL
Intervention: Maintaining high PAI scores (≥100 PAI at both examinations)
Number of subjects: 17613

Group type: EXPERIMENTAL
Intervention: Increasing PAI scores over time (PAI score of zero at first examination and ≥100 at last examination)
Number of subjects: 17613

Group type: EXPERIMENTAL
Intervention: Maintaining high PAI score
Number of subjects: 17613

Group type: EXPERIMENTAL
Intervention: Increasing PAI score over time
Number of subjects: 17613
Study: 33673786

Group type: EXPERIMENTAL
Intervention: Freeze all strategy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Freeze all treatment
Number of subjects: 10
Study: 32171760

Group type: EXPERIMENTAL
Intervention: Post-amendment inclusion criteria requiring elevated natriuretic peptides (B-type natriuretic peptide ≥200 ng/l or N-terminal pro-B-type natriuretic peptide ≥800 ng/l)
Number of subjects: 5022

Group type: COMPARATOR
Intervention: Rivaroxaban treatment
Number of subjects: 5022
Study: 36507206

Group type: EXPERIMENTAL
Intervention: Therapeutic aspiration of the knee joint
Number of subjects: 120
Study: 36094645

Group type: EXPERIMENTAL
Intervention: Donanemab (700 mg for the first 3 doses, then 1400 mg every 4 weeks for up to 72 weeks)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Donanemab
Number of subjects: 272
Study: 36070709

Group type: EXPERIMENTAL
Intervention: Lower glycemic criteria
Number of subjects: 4061

Group type: COMPARATOR
Intervention: Higher glycemic criteria
Number of subjects: 4061

Group type: EXPERIMENTAL
Intervention: Treatment for gestational diabetes
Number of subjects: 4061
Study: 34473823

Group type: EXPERIMENTAL
Intervention: Health promotion interventions targeting African American men; specific interventions not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally tailored health promotion efforts; specific interventions not detailed.
Number of subjects: 0
Study: 34218485

Group type: EXPERIMENTAL
Intervention: Patient-family carer partnership intervention over 10 weeks (five sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 44
Study: 33083465

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 80
Study: 33810868

Group type: EXPERIMENTAL
Intervention: Bicarbonate supplementation (7 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sodium chloride control (7 days)
Number of subjects: 14
Study: 32142725

Group type: EXPERIMENTAL
Intervention: Single-port robotic surgery
Number of subjects: 100
Study: 35718032

Group type: EXPERIMENTAL
Intervention: ZnO–NF1 (1.5 g/L photocatalyst)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZnO–NF2 (1.5 g/L photocatalyst)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZnO–NF2 (2 g/L photocatalyst)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZnO–NF1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZnO–NF2
Number of subjects: 0
Study: 34639439

Group type: EXPERIMENTAL
Intervention: Mobile mindfulness intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Online recruitment
Number of subjects: 123

Group type: COMPARATOR
Intervention: Traditional recruitment
Number of subjects: 123
Study: 35950470

Group type: EXPERIMENTAL
Intervention: tDCS and smart hand joint training device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (smart hand joint training device)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intervention group (tDCS and smart hand joint training device)
Number of subjects: 60
Study: 33302224

Group type: EXPERIMENTAL
Intervention: Telehealth consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face consultation (usual care)
Number of subjects: 0
Study: 33302678

Group type: EXPERIMENTAL
Intervention: Closed suction irrigation method
Number of subjects: 159

Group type: COMPARATOR
Intervention: Conventional primary wound closure
Number of subjects: 159
Study: 35416889

Group type: EXPERIMENTAL
Intervention: OMT combined with photobiomodulation (G1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: OMT combined with inactive laser (G2)
Number of subjects: 34
Study: 32920065

Group type: EXPERIMENTAL
Intervention: Riboflavin (1.6 mg/d for 16 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32865660

Group type: EXPERIMENTAL
Intervention: Sources of Strength (Sources) intervention in rural schools
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist control group (non-intervention schools)
Number of subjects: 20
Study: 34371324

Group type: EXPERIMENTAL
Intervention: Ketadex (dexmedetomidine 0.7 μg/kg and ketamine 1 mg/kg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Ketofol (propofol 0.5 mg/kg and ketamine 0.5 mg/kg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ketamine alone (1 mg/kg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ketadex vs Ketamine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ketofol vs Ketamine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 93
Study: 32303810

Group type: EXPERIMENTAL
Intervention: Random training perturbation schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Block training perturbation schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33419899

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Number of subjects: 384

Group type: COMPARATOR
Intervention: Without liner
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 384
Study: 35227404

Group type: EXPERIMENTAL
Intervention: Emotional Socialization Training (EST)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Family Accommodation Modification (FAM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined EST and FAM
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 80
Study: 32825989

Group type: EXPERIMENTAL
Intervention: Osteopathic treatments (OTs)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 82
Study: 36117146

Group type: EXPERIMENTAL
Intervention: Topical gabapentin 10%
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 32739607

Group type: EXPERIMENTAL
Intervention: Pneumatic Retinopexy (PnR)
Number of subjects: 388
Study: 35310422

Group type: EXPERIMENTAL
Intervention: 30 mg mirtazapine tablet
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone diluted in 100 ml of saline infusion
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 33268401

Group type: EXPERIMENTAL
Intervention: Progestin-primed ovarian stimulation (PPOS) protocol
Number of subjects: 392

Group type: COMPARATOR
Intervention: Flexible gonadotropin-releasing hormone (GnRH) antagonist protocol
Number of subjects: 392

Group type: COMPARATOR
Intervention: Both PPOS and GnRH antagonist protocols
Number of subjects: 392
Study: 34717820

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg twice daily for 10 days)
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1497
Study: 33757568

Group type: EXPERIMENTAL
Intervention: Active cycle of breathing techniques combined with phonophoresis
Number of subjects: 75

Group type: COMPARATOR
Intervention: Active cycle of breathing techniques
Number of subjects: 75

Group type: COMPARATOR
Intervention: Phonophoresis
Number of subjects: 75
Study: 34058110

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical and lifestyle therapy
Number of subjects: 0
Study: 34911183

Group type: EXPERIMENTAL
Intervention: Individualised counselling in addition to educational pamphlets
Number of subjects: 320

Group type: COMPARATOR
Intervention: Educational pamphlets alone (Control)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Individualised counselling
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Overall knowledge scores
Number of subjects: 320
Study: 33497809

Group type: COMPARATOR
Intervention: Nesiritide
Number of subjects: 883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Baseline IL-6
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: IL-6 at 48-72 hours
Number of subjects: 883
Study: 32828358

Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 36444919

Group type: COMPARATOR
Intervention: general information
Number of subjects: 735

Group type: COMPARATOR
Intervention: option grid
Number of subjects: 735

Group type: COMPARATOR
Intervention: option grid plus recommendation
Number of subjects: 735
Study: 33452123

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 35487475

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + saline solution (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + 2% chlorhexidine-gel (n = 10)
Number of subjects: 20
Study: 33649769

Group type: EXPERIMENTAL
Intervention: Self-identified race
Number of subjects: 2944

Group type: EXPERIMENTAL
Intervention: Cognitive scores across racial groups
Number of subjects: 2944

Group type: EXPERIMENTAL
Intervention: Proportion of African ancestry
Number of subjects: 2944
Study: 32886337

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Vehicle lotion (control)
Number of subjects: 1640